<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33848232</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>03</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Reduced mucosal immunity to poliovirus after cessation of trivalent oral polio vaccine.</ArticleTitle><Pagination><StartPage>2560</StartPage><EndPage>2567</EndPage><MedlinePgn>2560-2567</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2021.1911213</ELocationID><Abstract><AbstractText>The switch from using only trivalent oral polio vaccine (tOPV) to sequential schedules combining inactivated poliovirus vaccine (IPV) and bivalent oral polio vaccine (bOPV) for polio vaccination will cause changes to mucosal immunity against polio in infants, which plays an important role in preventing the poliovirus spread. Here, we analyzed mucosal immunity against poliovirus in the intestine during different sequential vaccination schedules. We conducted clinical trials in Guangxi Province, China on 1,200 2-month-old infants who were randomly assigned to one of three vaccination schedule groups: IPV-bOPV-bOPV, IPV-IPV-tOPV, and IPV-IPV-bOPV, with vaccine doses administered at 8, 12, and 16&#xa0;weeks of age. Stool samples were collected from 10% of participants in each group before administration of the second vaccine doses and at 1, 2, and 4&#xa0;weeks after the administrations of the second and third vaccine doses. Immunoglobulin A (IgA) in the stool samples was measured to analyze the mucosal immune response in the intestine. Because of the absence of poliovirus type 2 in bOPV, the vaccination schedule of IPV-IPV-bOPV did not sufficiently raise intestinal mucosal immunity against poliovirus type 2, although some cross-immunity was seen. The level of intestinal mucosal immunity was related to shedding status; shedders could produce intestinal mucosa IgA more quickly. The intestinal mucosal immunity level was not related to serum neutralizing antibody level. In the combined sequential vaccination schedule of IPV and bOPV, the risk of circulating vaccine-derived poliovirus type 2 (cVDPV2) may be increased owing to insufficient intestinal mucosal immunity against poliovirus type 2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Hongyuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hangzhou Women's Hospital Hangzhou Maternity and Child Health Care Hospital, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Rufei</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Yuting</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaochang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Tianjin Centers for Disease Control and Prevention, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Guoliang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaolei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zhimei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jingsi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Yunnan Key Laboratory of Vaccine Research &amp; Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018928" MajorTopicYN="N">Immunity, Mucosal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Intestinal mucosal immunity</Keyword><Keyword MajorTopicYN="N">inactivated poliovirus vaccine</Keyword><Keyword MajorTopicYN="N">oral polio vaccine</Keyword><Keyword MajorTopicYN="N">polio</Keyword><Keyword MajorTopicYN="N">sequential vaccination schedule</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>13</Day><Hour>17</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33848232</ArticleId><ArticleId IdType="pmc">PMC8475588</ArticleId><ArticleId IdType="doi">10.1080/21645515.2021.1911213</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . Two out of three wild poliovirus strains eradicated. 2019Oct24[accessed 2019 Oct
25]. https://www.who.int/news-room/feature-stories/detail/two-out-of-three-wild-poliovirus-strains-eradicated.</Citation></Reference><Reference><Citation>Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH.. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis. 1991;163(1):1&#x2013;6. doi:10.1093/infdis/163.1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/163.1.1</ArticleId><ArticleId IdType="pubmed">1845806</ArticleId></ArticleIdList></Reference><Reference><Citation>Laassri M, Lottenbach K, Belshe R, Wolff M, Rennels M, Plotkin S, Chumakov K. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis. 2005;192(12):2092&#x2013;98. doi:10.1086/498172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/498172</ArticleId><ArticleId IdType="pubmed">16288372</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Global eradication of wild poliovirus type 2 declared. 2015Sep20[accessed 2015 Oct
6] http://www.polioeradication.org/mediaroom/newsstories/Global-eradication-of-wild-poliovirus-type-2-declared/tabid/526/news/1289/Default.aspx.</Citation></Reference><Reference><Citation>Herremans MM, Van Loon AM, Reimerink JH, Rumke HC, Van Der Avoort HG, Kimman TG, Koopmans MP. Poliovirus-specific immunoglobulin A in persons vaccinated with inactivated poliovirus vaccine in The Netherlands. Clin Diagn Lab Immunol. 1997;4(5):499&#x2013;503. doi:10.1128/CDLI.4.5.499-503.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CDLI.4.5.499-503.1997</ArticleId><ArticleId IdType="pmc">PMC170580</ArticleId><ArticleId IdType="pubmed">9302194</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry JL, Jaikaran ES, Davies JR, Tomlinson AJ, Mason PJ, Barnes JM, Beale AJ. A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J Hyg (Lond). 1966;64(1):105&#x2013;20. doi:10.1017/S0022172400040389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0022172400040389</ArticleId><ArticleId IdType="pmc">PMC2134687</ArticleId><ArticleId IdType="pubmed">5219018</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, et al. Expert review on poliovirus immunity and transmission. Risk Anal. 2013;33(4):544&#x2013;605. doi:10.1111/j.1539-6924.2012.01864.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1539-6924.2012.01864.x</ArticleId><ArticleId IdType="pmc">PMC7896540</ArticleId><ArticleId IdType="pubmed">22804479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hird TR, Grassly NC, Andino R. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012;8(4):e1002599. doi:10.1371/journal.ppat.1002599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002599</ArticleId><ArticleId IdType="pmc">PMC3330118</ArticleId><ArticleId IdType="pubmed">22532797</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Ryan M, Bandyopadhyay AS, Villena R, Espinoza M, Novoa J, Weldon WC, Oberste MS, Self S, Borate BR, Asturias EJ, et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis. 2015;15(11):1273&#x2013;82. doi:10.1016/S1473-3099(15)00219-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)00219-4</ArticleId><ArticleId IdType="pubmed">26318714</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright PF, Connor RI, Wieland-Alter WF, Hoen AG, Boesch AW, Ackerman ME, Oberste MS, Gast C, Brickley EB, Asturias EJ, et al. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants. Lancet Infect Dis. 2016;16(12):1377&#x2013;84. doi:10.1016/S1473-3099(16)30169-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(16)30169-4</ArticleId><ArticleId IdType="pmc">PMC5611465</ArticleId><ArticleId IdType="pubmed">27638357</ArticleId></ArticleIdList></Reference><Reference><Citation>Valtanen S, Roivainen M, Piirainen L, Stenvik M, Hovi T. Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion. J Infect Dis. 2000;182(1):1&#x2013;5. doi:10.1086/315684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/315684</ArticleId><ArticleId IdType="pubmed">10882574</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright PF, Wieland-Alter W, Ilyushina NA, Hoen AG, Arita M, Boesch AW, Ackerman ME, Van Der Avoort H, Steven Oberste M, Pallansch MA, et al. Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination. J Infect Dis. 2014;209(10):1628&#x2013;34. doi:10.1093/infdis/jit671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit671</ArticleId><ArticleId IdType="pubmed">24459191</ArticleId></ArticleIdList></Reference><Reference><Citation>Resik S, Tejeda A, Mach O, Fonseca M, Diaz M, Alemany N, Heng Hung L, Aleman Y, Mesa I, Garcia G, et al. Does simultaneous administration of bivalent (types 1 and 3) oral poliovirus vaccine and inactivated poliovirus vaccine induce mucosal cross-immunity to poliovirus type 2? Clin Infect Dis. 2018;67(suppl_1):S51&#x2013;S6. doi:10.1093/cid/ciy604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciy604</ArticleId><ArticleId IdType="pmc">PMC6206124</ArticleId><ArticleId IdType="pubmed">30376088</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, Platt L, Mach O, Jafari H, Aylward RB. The new polio eradication end game: rationale and supporting evidence. J Infect Dis. 2014;210(Suppl 1):S434&#x2013;8. doi:10.1093/infdis/jiu222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu222</ArticleId><ArticleId IdType="pubmed">25316865</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. BMC Infect Dis. 2015;15(1):374. doi:10.1186/s12879-015-1113-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1113-7</ArticleId><ArticleId IdType="pmc">PMC4574397</ArticleId><ArticleId IdType="pubmed">26381878</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Statement of the twenty-sixth polio IHR emergency committee. 2020Oct22[accessed 2020 Oct
23] https://www.who.int/news/item/22-10-2020-statement-of-the-twenty-sixth-polio-ihr-emergency-committee.</Citation></Reference><Reference><Citation>Garon J, Seib K, Orenstein WA, Ramirez Gonzalez A, Chang Blanc D, Zaffran M, Patel M. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines. 2016;15(6):693&#x2013;708. doi:10.1586/14760584.2016.1140041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1140041</ArticleId><ArticleId IdType="pubmed">26751187</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Statement of the twenty-second IHR emergency committee regarding the international spread of poliovirus. 2019[accessed 2019 Oct
3]. https://www.who.int/news-room/detail/03-10-2019-statement-of-the-twenty-second-ihr-emergency-committee-regarding-the-international-spread-of-poliovirus.</Citation></Reference><Reference><Citation>Nicoletta Previsani RHT, Graham T, Jafari HS. Guidelines for containment of poliovirus following type-specific polio eradication&#x2014;worldwide. Morbidity and Mortality Weekly Report. 2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">26313474</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Coster I, Bandyopadhyay AS, Suykens L, Rudelsheim P, Neels P, Oberste MS, Weldon WC, Clemens R, Revets H, et al. Poliopolis: pushing boundaries of scientific innovations for disease eradication. Future Microbiol. 2019;14(15):1321&#x2013;30. doi:10.2217/fmb-2019-0196.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb-2019-0196</ArticleId><ArticleId IdType="pmc">PMC9186300</ArticleId><ArticleId IdType="pubmed">31482728</ArticleId></ArticleIdList></Reference><Reference><Citation>De Coster I, Leroux-Roels I, Bandyopadhyay AS, Gast C, Withanage K, Steenackers K, De Smedt P, Aerssens A, Leroux-Roels G, Oberste MS, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet. 2021;397(10268):39&#x2013;50. doi:10.1016/S0140-6736(20)32541-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32541-1</ArticleId><ArticleId IdType="pmc">PMC7811203</ArticleId><ArticleId IdType="pubmed">33308429</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. Evaluation of proactive and reactive strategies for polio eradication activities in Pakistan and Afghanistan. Risk Anal. 2019;39(2):389&#x2013;401. doi:10.1111/risa.13194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13194</ArticleId><ArticleId IdType="pmc">PMC7857157</ArticleId><ArticleId IdType="pubmed">30239026</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. Lessons from globally coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes. J Infect Dis. 2017;216(suppl_1):S168&#x2013;S75. doi:10.1093/infdis/jix128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix128</ArticleId><ArticleId IdType="pmc">PMC5853947</ArticleId><ArticleId IdType="pubmed">28838198</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopel E, Kaliner E, Grotto I. Lessons from a public health Emergency &#x2014; importation of wild poliovirus to Israel. N Engl J Med. 2014;371(11):981&#x2013;83. doi:10.1056/NEJMp1406250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1406250</ArticleId><ArticleId IdType="pubmed">25207764</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991;13(5):926&#x2013;39. doi:10.1093/clinids/13.5.926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinids/13.5.926</ArticleId><ArticleId IdType="pubmed">1660184</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, Cochi SL. Inactivated poliovirus vaccine supply shortage: is there light at the end of the tunnel? J Infect Dis. 2019;220(10):1545&#x2013;46. doi:10.1093/infdis/jiy739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiy739</ArticleId><ArticleId IdType="pmc">PMC10547123</ArticleId><ArticleId IdType="pubmed">30958545</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton EB, Bauer DL, Weldon WC, Oberste MS, Lawson LB, Clements JD. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. Vaccine. 2015;33(16):1909&#x2013;15. doi:10.1016/j.vaccine.2015.02.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.02.069</ArticleId><ArticleId IdType="pubmed">25765967</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>